Les antileucotrienes: une nouvelle classe de medicaments a integrer dans la strategie therapeutique de l'asthme. [The anti-leukotrienes: a new class of drugs to integrate into the therapeutic strategy of asthma]

Details

Serval ID
serval:BIB_BC9348B93779
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Les antileucotrienes: une nouvelle classe de medicaments a integrer dans la strategie therapeutique de l'asthme. [The anti-leukotrienes: a new class of drugs to integrate into the therapeutic strategy of asthma]
Journal
Revue Médicale de la Suisse Romande
Author(s)
Fellrath  J. M., Leuenberger  P., Weilenmann  C., Spertini  F.
ISSN
0035-3655 (Print)
Publication state
Published
Issued date
03/1999
Volume
119
Number
3
Pages
217-26
Notes
English Abstract
Journal Article
Review --- Old month value: Mar
Abstract
Leukotrienes play an important role in the pathogenesis of asthma, a chronic inflammatory disease. They are potent bronchoconstrictors and chemoattractants; furthermore, they increase vascular permeability and mucus secretion. Early treatment of bronchial inflammation has become an essential element of the therapeutic approach of asthma and relies mainly on inhaled corticosteroids. However, known adverse effects of inhaled corticosteroids raise important long-term questions on their local and systemic tolerance. These safety aspects have encouraged the development of other anti-inflammatory drugs. Antileukotrienes (specific antagonist of receptors and inhibitors of 5-lipoxygenase) display a beta 2-agonist additive effect, confer an effective protection in bronchial provocations, improve both clinical and functional asthma scores and also allow a decreasing in short-acting beta 2-agonist use. They are intended for patients suffering from persistent mild-to-moderate asthma. However, further studies are still required to determine both their long-term efficacity and tolerance, to define their place in the strategy of asthma management and finally to clarify their application in other allergic diseases.
Keywords
Anti-Asthmatic Agents/pharmacology/*therapeutic use Asthma/*drug therapy/immunology Disease Management Drug Interactions Humans Leukotriene Antagonists/*pharmacology/*therapeutic use Patient Care Planning Severity of Illness Index
Pubmed
Create date
25/01/2008 15:20
Last modification date
20/08/2019 15:30
Usage data